Highlights Insmed Incorporated

Equities

INSM

US4576693075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 14/03/2026 am IST			5-day change	1st Jan Change
139.50 ^USD	-0.01%		-0.45%	-19.85%

10/03	Insmed Incorporated Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 08:00 AM
02/03	Insmed Incorporated Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 09:50 AM

Highlights

23/02	MHRA says licensed brensocatib as first drug for non-cystic fibrosis bronchiectasis in patients aged 12+	RE
20/02	Insmed May Top Revenue Target for Bronchiectasis Drug Brinsupri, Morgan Stanley Says	MT
19/02	Insmed Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
19/02	The Market's Nerves Are Showing
19/02	Insmed reports fourth-quarter and full-year 2025 financial results and provides business update	RE
19/02	Insmed Q4 Loss Widens, Revenue Rises	MT
19/02	Earnings Flash (INSM) Insmed Incorporated Reports Q4 Revenue $263.8M, vs. FactSet Est of $237.8M	MT
19/02	Earnings Flash (INSM) Insmed Posts Q4 Loss $1.54 a Share, vs. FactSet Est of $1.02 Loss	MT
19/02	Insmed Incorporated Provides Earnings Guidance for the Full Year 2026	CI
09/01	Insmed Incorporated Provides Revenue Guidance for the Full Year 2025	CI
18/12	Inflation Took a Chill Pill
18/12	Stocks to Watch : Micron, MillerKnoll, HireQuest, Insmed	DJ
18/12	Insmed scraps development of sinus drug after mid-stage study failure	RE
18/12	Insmed Halts Brensocatib Development in CRSsNP After Trial Miss; Shares Fall After Hours	MT
18/12	Insmed provides clinical and business update	RE
18/12	Insmed Incorporated Provides Clinical and Business Update	CI
13/12	Bitcoin hoarding company Strategy remains in Nasdaq 100	RE
04/12	Insmed reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
19/11	Insmed Says European Commission Approves Brinsupri for Treatment of Non-Cystic Fibrosis Bronchiectasis	MT
18/11	Insmed Incorporated Receives European Commission Approval For BRINSUPRI As First Treatment For Non-Cystic Fibrosis Bronchiectasis	CI
06/11	Insmed Insider Sold Shares Worth $4,985,911, According to a Recent SEC Filing	MT
30/25/30	Insmed Incorporated Raises Global ARIKAYCE Revenue Guidance for the Full Year 2025	CI
30/25/30	Insmed Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
30/25/30	Insmed Q3 revenue beats estimates	RE
30/25/30	Insmed Q3 Loss Widens, Revenue Rises; Shares up	MT